SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Journal of Oncology Pharmacy Practice
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Skirvin, J. A.
Right arrow Articles by Morris, A. K.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Skirvin, J. A.
Right arrow Articles by Morris, A. K.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

6-Mercaptopurine hepatotoxicity during acute lymphocytic leukemia maintenance therapy

J. Andrew Skirvin, PharmD

College of Pharmacy, St. John's University, Jamaica, New York, Oncology Clinical Preceptor, North Shore University Hospital, Manhasset, New York

Amy W. Valley, PharmD, BCPS

South Texas Veterans Health Care System, Audie L. Murphy Memorial Veterans Hospital Division, University of Texas Health Science Center San Antonio, San Antonio, Texas

Valerie Relias, PharmD

New England Medical Center, Department of Pharmacy, Boston, Massachusetts

Ashley K. Morris, PharmD, BCPS

Duke University Medical Center, Department of Pharmacy, Durham, North Carolina

Purpose. To describe a case of 6-mercaptopurine acute fulminate hepatotoxicity.

Case Summary. A 65-year-old male with adult acute lymphocytic leukemia was receiving mainte nance therapy with 6-mercaptopurine and methotrex ate when he presented with jaundice, nausea, diar rhea, dysuria, right upper quadrant pain, and dark urine. He presented with elevated bilirubin, aspartate aminotransferase, and alanine aminotransferase. The work-up was negative for other causes of liver dam age. His hospital course included antibiotic therapy, vitamin K, and filgrastim. He was discharged without long-term morbidity from the event and had a normal ization of liver enzymes as an outpatient. Methotrex ate maintenance therapy was continued successfully as an outpatient for > 1 year.

Conclusion. 6-Mercaptopurine is not commonly considered as an agent causing acute hepatotoxicity, but should not be ruled out as a causative agent in the setting of concurrent methotrexate therapy. An epi sode of acute hepatotoxicity did not preclude the continued, safe use of methotrexate in this case.

Key Words: 6-Mercaptopurine • methotrexate; hepatotoxicity • acute lymphocytic leukemia.

Journal of Oncology Pharmacy Practice, Vol. 4, No. 2, 117-120 (1998)
DOI: 10.1177/107815529800400203


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?




Advertisement